Our study presents a new mechanism for GLP1-RA treatment in obese kidneys: namely, the GLP1-RA exenatide can rescue SIRT1, which can ameliorate obesity-induced mitochondrial dysfunction, the overproduction of ROS and apoptosis. Here, GLP1R is linked to obesity disorder.